Risks

High net debt to EBITDA and sub-1.0 liquidity ratios leave TEVA more exposed than many branded-drug peers if pricing or volume pressure weakens cash generation.

Interest coverage above 3x still leaves limited cushion versus stronger peers, so higher rates or earnings volatility could constrain refinancing flexibility and deleveraging pace.

A 95-day cash conversion cycle and 141-day inventory build tie up working capital more than leaner peers, increasing execution risk if demand or supply normalizes unevenly.

Elevated leverage and working-capital intensity make TEVA less resilient than diversified pharma peers, so any setback in generics or specialty execution would transmit faster to equity value.

Opportunities

TEVA’s scale in generics and specialty medicines supports broader market access than smaller peers, creating upside if volume recovery and mix improvement continue.

If deleveraging continues, lower interest burden and improved balance-sheet flexibility could expand earnings quality faster than for more levered generic peers.

Working-capital normalization from elevated inventory and receivables could release cash, improving free-cash-flow conversion relative to peers with steadier operating cycles.

A more diversified product base than single-therapy peers gives TEVA multiple external demand drivers, which can cushion category-specific weakness and support steadier growth.

Overall Score

TEVA’s scale and diversification support upside, but elevated leverage, tight liquidity, and working-capital intensity keep realized outcomes more constrained than stronger peers.